# Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A)

> **NCT00430521** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 512 (actual)

## Conditions studied

- Influenza
- Influenza Vaccines

## Interventions

- **BIOLOGICAL:** Pandemic influenza vaccine (GSK1119711A)-formulation 1
- **BIOLOGICAL:** Pandemic influenza vaccine (GSK1119711A)-formulation 2

## Key facts

- **NCT ID:** NCT00430521
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02-05
- **Primary completion:** 2008-10-20
- **Final completion:** 2008-10-20
- **Target enrollment:** 512 (ACTUAL)
- **Last updated:** 2019-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00430521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00430521, "Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A)". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00430521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*